Sotsiaalministeerium · 13. jaanuar 2021
Sisu (failidest)
EJP RD JTC 2021: MoU
European Joint Programme on Rare Diseases
(EJP RD)
Call for Proposals 2021
"Social sciences and Humanities Research
to improve health care implementation and everyday life of people
living with a rare disease”
Memorandum of Understanding (MoU) on
International Cooperation in Research
Funding
within the Framework of the EJP on Rare
Diseases
JTC 2021
Established between the following Participants:
• Austrian Science Fund (FWF), Austria
• Research Foundation Flanders (FWO), Belgium, Flanders
• Fund for Scientific Research - FNRS (F.R.S.-FNRS), Belgium, Wallonia-Brussels
Federation
• Canadian Institutes of Health Research – Institute of Genetics (CIHR-IG),
Canada
• Ministry of Social Affairs (MOSAE), Estonia
• French National Research Agency (ANR), France
• Federal Ministry of Education and Research (BMBF), Germany
• National Research, Development and Innovation Office (NKFIH), Hungary
• Chief Scientist Office of the Ministry of Health (CSO-MOH), Israel
• Italian Ministry of Health (MoH-IT), Italy
• Tuscany Region (RT/TuscReg), Tuscany (Italy)
• Research Council of Lithuania (LMT), Lithuania
• National Research Fund (FNR), Luxembourg
• National Centre for Research and Development (NCBR), Poland
• Slovak Academy of Sciences (SAS), Slovakia
• National Institute of Health Carlos III (ISCIII), Spain
• Swiss National Science Foundation (SNSF), Switzerland
1
EJP RD JTC 2021: MoU
• The Scientific and Technological Research Council of Turkey (TUBITAK), Turkey
• The French National Institute of Health and Medical Research (INSERM),
France (will provide dedicated funding only to Patient Advocacy Organisations).
2
EJP RD JTC 2021: MoU
INTRODUCTION
There are at least 7000 distinct rare diseases, the great majority being of genetic origin.
Although individually rare, taken together rare diseases affect at least 26-30 million
people in Europe. Moreover, they represent a major issue in health care: a large
number of these diseases have an early or very early onset and/or lead to a significant
decrease of life expectancy. Moreover, most of them cause chronic illnesses with a
large impact on quality of life and the health care system.
Therefore, research on rare diseases is needed to provide knowledge for prevention,
diagnosis, better care and everyday life improvement for patients. Yet, research is
hampered by lack of resources at several levels: (1) Few scientists work on any given
specific disease, (2) There are few patients per disease and they are scattered over
large geographic areas, causing difficulties to assemble the necessary cohorts, (3)
Existing databases and bio-material collections are usually local, small, and not
accessible or standardized, (4) The complex and multiple problematics of these
diseases require interdisciplinary cooperation to improve everyday life and care.
Health is more than bioscience and medicine. Health also strongly relies on adequate
social, psychological, cultural and historical resources. Care is more than healthcare:
it is “the provision of what is necessary for the health, welfare, maintenance, and
protection of someone or something”. Social sciences and Humanities (SSH) help
understanding all dimensions of health and care: human condition, suffering,
personhood, our responsibility to each other, implementation within cultural and social
contexts. Therefore, SSH research in the field of rare diseases is of crucial importance
to help better understanding and better implementation of solutions for those living
with a rare disease.
The specificities of rare diseases - limited number of patients per disease, scarcity of
relevant knowledge and expertise, and fragmentation of research - single them out
as a distinctive domain of very high European added-value. Rare diseases are
therefore a prime example of a research area that necessitates
collaboration/coordination on a transnational scale.
In this context, the European Joint Programme on Rare Diseases (EJP RD) has
successfully implemented two Joint Transnational Calls since 2019 to further help in
coordinating the research efforts of European, Associated and non-European
countries in the field of rare diseases and implement the objectives of the International
Rare Disease Research Consortium (IRDiRC). These actions are following the ten Joint
Transnational Calls for rare diseases research projects launched previously by the ERA-
Net E-Rare since 2006. The aim of the call is in compliance with the vision and goals set
by the International Rare Diseases Research Consortium (IRDiRC) which fosters
international collaboration in rare diseases research.
Under the umbrella of the EJP RD the above listed Participants decided to open the
joint call for funding multilateral research projects on rare diseases (JTC 2021) whose
details are agreed by the Participants as stated below.
3
EJP RD JTC 2021: MoU
NOW, THEREFORE, THE PARTICIPANTS HAVE REACHED THE FOLLOWING
UNDERSTANDING:
1. PURPOSE OF THIS MoU
The aim of this Memorandum of Understanding (MoU) is to establish the principles
and procedures to be adopted by all Parties in the Joint Transnational Call JTC 2021:
• Launching a common call for proposals
• Receiving collaborative proposals
• Setting up a common evaluation and selection procedure
• Providing funding for the proposals selected according to the final
ranking list.
2. CONTENT OF THE CALL
The Participants will launch a transnational programme on "Social sciences and
Humanities Research to improve health care implementation and everyday life of
people living with a rare disease” which will be jointly managed and financed by the
Participants that are members of the EJP RD, according to their respective legal
framework and regulations. The programme will be implemented by a call for
proposals to be launched and processed in 2020-2021. The call will be opened
simultaneously by the Participants in their respective countries and regions.
3. GOVERNANCE OF THE CALL AND EVALUATION PROCEDURE
The governance of the call, its organization and the evaluation procedures are
detailed in the document “Governance of the call and evaluation procedure” (i.e.
Annex 1 to this MoU).
All decisions concerning the JTC 2021 call procedures and transnational project
funding will be taken by the Call Steering Committee (CSC) together with the
European Commission. The Joint Call Secretariat (JCS) of JTC 2021 is organised by the
French Foundation for Rare Diseases (FFRD), France. The responsibilities of the CSC and
the JCS are detailed in the document “Governance of the call and evaluation
procedure”. The scientific assessment of applications will be led by a Scientific
Evaluation Committee (SEC) on the basis of scientific quality and evaluation criteria as
specified in the document “Governance of the call and evaluation procedure”. The
CSC will select proposals for funding according to the reviews and the final ranking list
established by the SEC. Subsequently the final decision will be made by the respective
4
EJP RD JTC 2021: MoU
national/regional funding organisations subject to availability of funds and in
compliance with applicable regulations and legal provisions.
A two-stage submission and evaluation procedure for joint proposals with a rebuttal
stage will be applied.
4. ELIGIBILITY OF APPLICATIONS
The eligibility of institutions, patient organisations and costs, as well as complementary
administrative requirements are subject to the country and/or regional Participant’s
regulations and legal framework and may therefore vary from one Participant to
another. Information needs to be provided on time and form according to relevant
Participant’s regulations for research funding. The general eligibility rules for this call
are specified in the call text and the national/regional criteria in the guidelines
document.
5. FUNDING BUDGETS AND PROCEDURES
The envisaged contribution by each Participant is listed below as follow:
Envisaged amount of
Country/Region Participant funding (M€ for 3
years) is up to:
Austria FWF 0.6
Belgium/Flanders FWO 0.35
Belgium/French
F.R.S.-FNRS 0.24
speaking community
CIHR-IG, in partnership with Ataxia
Canada Charlevoix-Saguenay Foundation $1.5 CAD
and Muscular Dystrophy Canada
Estonia MoSAE 0.075
France ANR 2
Germany BMBF 3
Hungary NKFIH 0.2
Israel CSO/MOH 0.2
Italy MoH-IT 0.5
Italy RT/TuscReg 0.3
Lithuania LMT 0.1
5
EJP RD JTC 2021: MoU
Luxembourg FNR 0.3
Poland NCBR 0.6
Slovakia SAS 0.12
Spain ISCIII 0.5
Switzerland SNSF 0.56*
Turkey TUBITAK 0,3
Multinational, funding
INSERM 0.3
for PAO
*The SNSF has earmarked a budget of 0.6 Mio Swiss Francs over three years (currently equivalent to 0.56
Mio. €)
The funds provided by the Participants to this MoU (table above) will be used for
research projects carried out by research centres and institutions according to their
respective countries’ regulations and legal framework and based on the scientific
quality of the proposals reflected by the SEC evaluation decision.
The proposals will be funded in accordance with the ranking order as a result of the
SEC advice, starting with the top-scoring proposals. In order to avoid early funding
gaps, each Participant participating in the joint call is asked to match as accurately
and realistically as possible the financial demand from the proposals with the budget
earmarked for the call. The final decision on funding will be made by the respective
Participants involved in the application. The respective Participants will make their
decision based on the information provided by the CSC and recommendations from
the SEC. Selected projects will receive funding directly from the corresponding
Participant’s subject to availability of funds and in compliance with applicable
regulations and legal provisions.
Funding will be awarded and administered according to the terms and conditions of
responsible Participant taking into account all other applicable national/regional
regulations and legal framework.
6. EU Budget
The EU budget corresponds for this call to the remaining EU Top-Up budget from
JTC2019 and JTC2020, after consultation and vote of the Board of Funders of JTC2019
and 2020.
The EU budget assigned to this call is 389,775€ will be administrated by INSERM for
funding of Patient Advocacy Organisations from participating countries.
Exceptions:
Estonian PAOs cannot be funded directly by INSERM.
Participating Spanish patients organizations (PAOs) cannot be funded by ISCIII directly,
PAOs could be financed via subcontracting, provided that they develop research
6
EJP RD JTC 2021: MoU
activities and the criteria for subcontracting detailed in the Spanish Act 38/2003, of
November 17th are fulfilled.
PAOs from Italy applying in collaboration with IRCCS funded by the MoH-IT, can
participate in a Consortium as a “collaborators” with their own funding or can be
financed as “sub-contractors” through the IRCCS’s budget. In any case, they cannot
be funded by INSERM directly with the budget left from the previous co-funded calls.
This decision was made to avoid blocking situation in case of oversubscription for PAOs
and allow the maximum funding of projects with PAOs involved (with a maximum
amount of 25,000€ per projects for PAOs), and to ensure adequate patient
participation in this very patient centric call.
7. REPORTING
The coordinators of all funded projects must submit brief annual scientific project
reports and a final scientific project report in the form of an online questionnaire. This
monitoring will be the role of CSH-MOH, Israel, and FNRS, Belgium, which is responsible
for the online monitoring system for the funded projects.
In addition, each team may have to report to its funding organisation, in accordance
with the respective national/regional funding organisations’ regulations.
8. CONFIDENTIALITY
Information exchanged between Participants in the scope of the present MoU is
deemed to be confidential within the funders of the JTC2021 unless stated otherwise
in writing.
In particular, the content of the proposals received under this call is deemed to be
confidential, except for the lists of applications and lists of projects selected for
funding. This commitment will survive the expiration or termination of this MoU but shall
not apply for disclosure or use of information, if a Participant is required to disclose
information in order to comply with applicable laws or regulations or with a court or
administrative order.
9. TERM AND AMENDMENTS
For each Participant, the MoU will come into force on the date of signature by the
Participant’s authorized representative. It shall cover the entire funding period of the
joint call research projects at least until all commitments are settled (expected to start
early in 2022 and to last at least 3 years), except force majeure, and including any
extension period to be specified later in writing.
The MoU may be amended and modified by written agreement of all Participants.
10. GDPR
The Participants will take all necessary measures to process personal data collected
and/or received in the scope of the application of this MoU in compliance with
7
EJP RD JTC 2021: MoU
personal data protection rules and laws applicable to them. For participants within the
European Union, this includes Regulation (EU )2016/679 of the European Parliament
and the Council of 27 April 2016 on the protection of natural persons with regard to
the processing of personal data and on the free movement of such data, and
repealing Directive 95/46/EC (General Data Protection Regulation) included.
11. ANNEXES
List of annexes to this MoU:
Annex 1: EJP RD JTC 2021 Call Steering Committee (CSC) composition
Annex 2: Details on the implementation of the joint call are outlined in the document
“Governance of the call and evaluation procedure”
12. SIGNATURES
8
EJP RD JTC 2021: MoU
For Research Foundation - Flanders (FWO), Flanders, Belgium
NAME: Dr. Hans Willems
POSITION: Secretary General
Signatures:
Date:
10
EJP RD JTC 2021: MoU
For Fund for Scientific Research - FNRS (F.R.S.-FNRS), Belgium
NAME: Dr. Ir. Véronique Halloin
POSITION: Secretary General
F.R.S.-FNRS
Signature:
Date: Brussels, December 17th, 2020
11
EJP RD JTC 2021: MoU
For Canadian Institutes of Health Research Institute of Genetics (CIHR-IG)
NAME: Dr. Christopher McMaster
POSITION: Scientific Director, CIHR Institute of Genetics
Signature:
Date: Dec 18, 2020
12
EJP RD JTC 2021: MoU
For French National Research Agency (ANR), France
NAME: Thierry Damerval
POSITION: Président Directeur Général
Signature:
Date: 16/12/2020
1
EJP RD JTC 2021: MoU
For Ministry of Health – Ministero della Salute (MOH-IT), Italy
NAME: Dr. Gaetano Guglielmi
POSITION: Head Office 3 Health Research, Deputy Director General - Directorate
General for Health Research and Innovation
Signature:
Date:
18
• EUROPEAN JOINT PROGRAMME EJP RD JTC 2021: MoU
1'- RARE DISEASES
For Slovak Academy of Sciences (SAS), Slovakia
NAME: Prof. Pavol ŠAJGALíK
POSITION: President
Signoture:
Date: ,~b, 12 . 2ó 2 O
23
EJP RD JTC 2021: MoU
Código seguro de Verificación : GEN-f9e3-d192-79e8-39f6-c310-6fe9-d784-1526 | Puede verificar la integridad de este documento en la siguiente dirección : https://sede.administracion.gob.es/pagSedeFront/servicios/consultaCSV.htm
For National Institute of Health Carlos III [Instituto de Salud Carlos III (ISCIII)]* Spain
NAME: Dr. Raquel Yotti Álvarez
POSITION: General Director
Signature:
Date:
25
*The funding commitment is subject to the approval of the General State Budget for 2021
CSV : GEN-f9e3-d192-79e8-39f6-c310-6fe9-d784-1526
DIRECCIÓN DE VALIDACIÓN : https://sede.administracion.gob.es/pagSedeFront/servicios/consultaCSV.htm
FIRMANTE(1) : RAQUEL YOTTI ALVAREZ | FECHA : 30/11/2020 20:32
EJP RD JTC 2021: MoU
For Swiss National Science Foundation (SNSF)
NAME: Dr. Irene Knüsel
POSITION: Head, Division Biology and Medicine, Swiss National Science
Foundation
Signature:
Date: December 17, 2020
25
EJP RD JTC 2021: MoU
For the French National Institute of Health and Medical Research (INSERM), France
NAME: P/ Madame Camille Chaudonneret
POSITION: Délégué Régionale
Signature:
Date: December 28, 2020
27
EJP RD JTC 2021: MoU
ANNEX1: EJP RD JTC 2021 Call Steering Committee (CSC) composition
Austrian Science Fund (FWF), Austria
Representative
Name: Dr. Stephanie Resch
Position: Scientific officer
Proxy
Name: Anita Stuertz, Dipl.-Ing.
Position: Operational Project Officer
Research Foundation - Flanders (FWO), Flanders, Belgium
Representative
Name: Alain Deleener
Position: Science Policy Advisor Strategic Research Programmes
Proxy
Name: Toon Monbaliu
Position: Advisor Research Affairs
Fund for Scientific Research - FNRS (F.R.S.-FNRS), Belgium
Representative
Name: Florence Quist
Position: Scientific officer
Proxy
Name: Joël Groeneveld
Position: Senior Policy officer
Canadian Institutes of Health Research (CIHR-IG), Canada
Representative
Name: Etienne Richer
Position:
Proxy
Name: Marilyn Desrosiers
Position: Deputy Director, Strategic Program Design and Analytics, CIHR
28
EJP RD JTC 2021: MoU
Ministry of Social Affairs (MoSAE), Estonia
Representative
Name: Heli Paluste
Position: Head of Health Care Unit
Proxy
Name: Mari Teesalu
Position: Research Adviser for Health Policy
French National Research Agency (ANR), France
Representative
Name: Dr. Florence Guillot
Position: Scientific Coordinator
Federal Ministry of Education and Research (BMBF), Germany
Representative
Name: Dr. Ralph Schuster
Position: Scientific officer
Proxy
Name: Dr. Katarzyna Saedler
Position: Scientific officer
Name: Dr. Michaela Fersch
Position: Scientific officer
National Research, Development and Innovation Office (NKFIH), Hungary
Representative
Name: Dr. Gábor Tóth
Position: Head of Unit, Unit for Medical and Biological Sciences
Proxy
29
EJP RD JTC 2021: MoU
Name: Dr. Előd Nemerkényi
Position: Assistant of International Affairs
Chief Scientist Office, Ministry of Health (CSO-MOH), Israel
Representative
Name: Prof. Avi Israeli
Position: Chief Scientist
Proxy
Name: Dr. Irit Allon
Position:
Ministry of Health – Ministero della Salute (MOH), Italy
Representative
Name: Dr. Gaetano Guglielmi
Position: Head Office 3 (Health Research – IRCCS)
Proxy
Name: Dr. Monica Paganelli – Dr. Raffaele Ruocco
Position: Scientific Officers
Tuscany Region (RT/TuscReg), Tuscany (Italy)
Representative
Name: Donatella Tanini
Position:
Proxy
Name: Teresa Vieri
Position:
Research Council of Lithuania (LMT), Lithuania
Representative
Name: Živilė Ružele
Position: Chief Officer
Proxy
Name: Jūratė Devižienė
Position: Head of International Programmes Unit
30
EJP RD JTC 2021: MoU
National Research Fund (FNR), Luxembourg
Representative
Name: Sean Sapcariu
Position: Programme Manager
Proxy
Name: Marie-Claude Marx
Position: Programme Manager
National Centre for Research and Development (NCBR), Poland
Representative
Name: Marcin Chmielewski
Position: Programme officer
Slovak Academy of Sciences (SAS), Slovakia
Representative
Name: Zuzana Cernakova, PhD
Position: Programme officer
Proxy
Name: Ing. Katarina Bibova
Position: Programme officer
National Institute of Health Carlos III (ISCIII), Spain
Representative
Name: Ignacio Baanante
Position: Head of the EU and Internationalization Division [EU+Int]
Proxy
Name: Gonzalo Arévalo
Position: Deputy General Director for International Research Programmes and
Institutional Relations
Swiss National Science Foundation (SNSF), Switzerland
Representative
Name: Dr. Florence Ettlin
Position: Scientific officer
31
EJP RD JTC 2021: MoU
The Scientific and Technological Research Council of Turkey (TUBITAK), Turkey
Representative
Name: Dr. Jale Şahin
Position: Programme officer
The French National Institute of Health and Medical Research (INSERM), France
Funding Patient Advocacy Organisation
Representative
Name: Dr. Daria Julkowska
Position: Programme officer
32